Penn Bioethics Seminar Series (PBS): "Capitalizing a Cure: How Finance Controls the Price and Value of Medicines" led by Victor Roy, MD, PhD

12:00pm - 1:00pm • Hybrid: 1402 Blockley Hall, 423 Guardian Drive (and virtual via Zoom)

2025-02-18 12:00:00 2025-02-18 13:00:00 America/New_York Penn Bioethics Seminar Series (PBS): "Capitalizing a Cure: How Finance Controls the Price and Value of Medicines" led by Victor Roy, MD, PhD Capitalizing a Cure: How Finance Controls the Price and Value of Medicines Victor Roy, MD, PhD Assistant Professor, Family Medicine and Community Health Hospital of the University of Pennsylvania How can we make sense of the rising role of financial actors and logics in the U.S. health system and its consequences? To answer this question, this talk will apply sociological analysis of so-called "financialization" in the broader economy to cases in health and raise questions about assets and ownership, value and valuation, and hegemonic knowledge practices. The talk will draw on his book-length project Capitalizing a Cure: How Finance Controls the Price and Value of Medicines (2023, University of California Press), which focused on pricing and valuation of curative hepatitis C medicines, and a co-authored perspective piece "The Financialization of Health in the United States" (2024, New England Journal of Medicine). Lunch provided. Streaming available via Zoom. Hybrid: 1402 Blockley Hall, 423 Guardian Drive (and virtual via Zoom) Penn Medical Ethics

How can we make sense of the rising role of financial actors and logics in the U.S. health system and its consequences? To answer this question, this talk will apply sociological analysis of so-called "financialization" in the broader economy to cases in health and raise questions about assets and ownership, value and valuation, and hegemonic knowledge practices. The talk will draw on his book-length project Capitalizing a Cure: How Finance Controls the Price and Value of Medicines (2023, University of California Press), which focused on pricing and valuation of curative hepatitis C medicines, and a co-authored perspective piece "The Financialization of Health in the United States" (2024, New England Journal of Medicine).